[Treatment of chronic cerebrovascular insufficiency and chronic obliterating arteriopathy of the lower extremities with buflomedil hydrochloride].
Research has been carried out into the effects of a new vasoactive substance, buflomedil hydrochloride, on two groups of patients suffering from cerebrovascular insufficiency and obliterating arteriopathy at the lower extremities. Ten clinical parameters were assessed in the first group of patients (insomnia, headache, vertigo, tinnitus, asthenia, shaking, changes in reflexes, anorexia, memory disturbances, problems of concentration and character disturbances); in the second group, the muscular flow of the gastrocnemius as measured by the muscular clearance of NaI131 at rest, during standard exercise conditions, during ten minutes following exercise and in the post-ischaemic phase. The results can be considered satisfactory in both groups, especially after prolonged treatment and in the early stage of the disease. Drug tolerance was very good.
D000368:Aged; D000855:Anorexia / Q000188:drug therapy; D001162:Arteriosclerosis Obliterans / Q000188:drug therapy*; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D004361:Drug Tolerance; D005260:Female; D006261:Headache / Q000188:drug therapy; D006801:Humans; D008297:Male; D008569:Memory Disorders / Q000188:drug therapy; D008875:Middle Aged; D009132:Muscles / Q000378:metabolism; D010554:Personality Disorders / Q000188:drug therapy; D005082:Physical Exertion; D011759:Pyrrolidines / Q000627:therapeutic use*; D012018:Reflex / Q000187:drug effects; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy; D012964:Sodium / Q000378:metabolism; D014012:Tinnitus / Q000188:drug therapy; D014202:Tremor / Q000188:drug therapy; D014717:Vertigo / Q000188:drug therapy
D011759:Pyrrolidines; D012964:Sodium; C010651:buflomedil
Trattamento dell'insufficienza cerebro-vascolare cronica e dell'arteriopatia obliterante cronica degli arti inferiori con buflomedil cloridrato.